HospitalsNovember 3, 2014

EPA Issues Updated Ebola Claim Guidance

by Halosil

Working closely with CDC, EPA has recently posted Ebola claims guidance on its Antimicrobial Policy and Guidance Documents webpage.

The Agency is not allowing specific label claims related to efficacy against the virus. However, if a product meets the CDC guidelines published in August 2014, companies can identify products on their websites and in non-label marketing.

Guideline Compliance

To comply with CDC guidelines, a product must have a label claim against at least one non-enveloped virus. Common ones include:

• Norovirus, hepatitis A, rotavirus, adenovirus, poliovirus, parvovirus, rhinovirus

While not stated in the EPA guidance, Antimicrobial Test Laboratories believes that disinfectants being used for surface disinfection against the Ebola virus should also be approved for use in hospitals since the CDC refers to products in its guidance as ‘hospital disinfectants.’ Hospital disinfectants are those products effective against BOTH Staphylococcus aureus and Pseudomonas aeruginosa.

Disinfectant Guidances

The Halo Disinfection System^TM meets both the EPA and CDC guidances for disinfectants with efficacy against non-enveloped viruses and as such, can be used for surface disinfection to protect against the spread of the deadly Ebola virus.

Sanosil International is actively working with numerous US hospitals, Western African governmental groups and providers of public transportation including airlines, ambulances and subway systems. Disinfection practices and protocols for many have become a top priority. Organizations are scrutinizing and rapidly updating minimally effective and human labor intensive procedures such as spraying and wiping in order to minimize the potential for transmission of the disease.

More information on Sanosil International’s rapidly deployable, cost effective and easy-to-train technology is available at sanosilinternational.com/ebola.